Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Haemophilus Influenzae Type b (Hib) Infection

Conditions

Haemophilus Influenzae Type b (Hib) Infection

Trial Timeline

Aug 1, 2009 → Apr 1, 2010

NCT ID

NCT01125527

About Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)

Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) is a phase 3 stage product being developed by Novartis for Haemophilus Influenzae Type b (Hib) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01125527. Target conditions include Haemophilus Influenzae Type b (Hib) Infection.

What happened to similar drugs?

2 of 8 similar drugs in Haemophilus Influenzae Type b (Hib) Infection were approved

Approved (2) Terminated (0) Active (6)

🔄Comparator: Modified Process Vaccine + Comparator: COMVAX™MerckPhase 3

✅Vaxelis + PedvaxHIBMerckApproved

🔄Haemophilus influenzae type b (Hib) vaccineNovartisPhase 3

✅Haemophilus influenza type b conjugate vaccineNovartisApproved

🔄Hib-CRM197 + Hib-TTNovartisPhase 3

🔄Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01125527	Phase 3	Completed	Aug 1, 2009	Apr 1, 2010	Haemophilus Influenzae Type b (Hib) Infection

Competing Products

10 competing products in Haemophilus Influenzae Type b (Hib) Infection

See all competitors

Product	Company	Stage	Hype Score
Comparator: Modified Process Vaccine + Comparator: COMVAX™	Merck	Phase 3	40
Vaxelis + PedvaxHIB	Merck	Approved	43
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Haemophilus influenzae type b (Hib) vaccine	Novartis	Phase 3	40
Haemophilus influenza type b conjugate vaccine	Novartis	Approved	43
Hib-CRM197 + Hib-TT	Novartis	Phase 3	40
Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)	Novartis	Phase 3	40
Haemophilus influenzae type b	Novartis	Phase 1	29
Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine	Novartis	Phase 3	40
DTaP-IPV/Hib	Sanofi	Pre-clinical	26